Hilleman Laboratories

Dr Rao will replace Dr Davinder Gill, who will leave his current role as CEO on 31st January, 2020, after more than eight years at…

Hilleman Laboratories also announced plans to venture into the area of maternal and child health

Collaboration seeks to accelerate the development, licensure, manufacture and supply of an affordable, next-generation cholera…

Hilleman Laboratories has recently initiated phase I/ II clinical trials for both rotavirus and cholera vaccines in Bangladesh. Dr…

Dr Davinder Gill, CEO, Hilleman Laboratories, roots for an educational programme for vaccinators to hone their skills and make…

The company is developing a synthetic vaccine to fight meningitis in Asian, African and Latin American countries Hilleman…

Receives the ‘100 most influential CFO’s of India’ and Best CFO of the year -Pharmaceutical and Biotech award Naveen Amar,…

The unique formulation will not only be cost effective but also scalable for commercial manufacturing Global vaccine research and…

The company plans to support India’s aim of achieving 90 per cent coverage through its expanded programme by 2020

The company plans to support India’s aim of achieving 90 per cent coverage through its expanded programme by 2020